Related Experiment Video

Updated: Sep 7, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

253

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V2) Therapy

Kyle C Roche1, Peter A DeRosa2, Min-Ling Liu3,4

  • 1Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

Current Oncology (Toronto, Ont.)
|June 23, 2022
PubMed

Insights

Standard treatments for refractory splenic marginal zone lymphoma (SMZL) are lacking. A patient with refractory SMZL showed a significant response to a combination of Venetoclax and Velcade (V2), a novel therapeutic approach.

Area of Science:

  • Hematology
  • Oncology
  • Lymphoma Research

Background:

  • Refractory splenic marginal zone lymphoma (SMZL) lacks established treatment protocols.
  • Investigating novel therapeutic strategies for relapsed or refractory B-cell lymphomas is crucial.

Observation:

  • A patient with refractory SMZL, previously treated with multiple therapies, was administered a combination of Venetoclax and Velcade (V2).
  • The patient exhibited a notable clinical response to this V2 combination therapy.

Findings:

  • The V2 combination demonstrated efficacy in a patient with refractory SMZL.
  • A unique histopathological and mutational profile was identified in this SMZL case.

Implications:

  • The V2 combination may represent a potential new treatment avenue for refractory SMZL.
  • The identified histopathology and mutational profile could impact SMZL characterization and prognosis.
Keywords:
Bortezomib (Velcade)Venetoclaxchemotherapy refractoryprogression without transformationrelapsed/refractory (R/R)splenic marginal zone lymphoma (SMZL)

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K